Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors

Maria Reinecke, Paul Brear, Larsen Vornholz, Benedict Tilmann Berger, Florian Seefried, Stephanie Wilhelm, Patroklos Samaras, Laszlo Gyenis, David William Litchfield, Guillaume Médard, Susanne Müller, Jürgen Ruland, Marko Hyvönen, Mathias Wilhelm, Bernhard Kuster

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Medicinal chemistry has discovered thousands of potent protein and lipid kinase inhibitors. These may be developed into therapeutic drugs or chemical probes to study kinase biology. Because of polypharmacology, a large part of the human kinome currently lacks selective chemical probes. To discover such probes, we profiled 1,183 compounds from drug discovery projects in lysates of cancer cell lines using Kinobeads. The resulting 500,000 compound–target interactions are available in ProteomicsDB and we exemplify how this molecular resource may be used. For instance, the data revealed several hundred reasonably selective compounds for 72 kinases. Cellular assays validated GSK986310C as a candidate SYK (spleen tyrosine kinase) probe and X-ray crystallography uncovered the structural basis for the observed selectivity of the CK2 inhibitor GW869516X. Compounds targeting PKN3 were discovered and phosphoproteomics identified substrates that indicate target engagement in cells. We anticipate that this molecular resource will aid research in drug discovery and chemical biology. (Figure presented.).

Original languageEnglish
Pages (from-to)577-585
Number of pages9
JournalNature Chemical Biology
Issue number5
StatePublished - May 2024


Dive into the research topics of 'Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors'. Together they form a unique fingerprint.

Cite this